Oscar Health (NYSE:OSCR) Sets New 52-Week High – Here’s Why

Oscar Health, Inc. (NYSE:OSCR) reached a new 52-week high on Tuesday. The stock traded as high as $34.80 and last traded at $34.5370, with a volume of 44,091 shares. The stock had previously closed at $34.01.

Key Stories Impacting Oscar Health

Here are the key news stories impacting Oscar Health this week:

• Positive Sentiment: Oscar Health raised its 2026 operating earnings outlook to $500 million-$700 million, citing pricing improvements and technology-driven efficiency gains. The upgraded guidance reinforces the company’s improving margin profile, although higher medical costs and member churn remain challenges. Oscar Health Raises 2026 Operating Earnings Outlook as Margins Improve
• Positive Sentiment: Recent coverage points to rapid membership growth, better medical economics and lower administrative expense ratios as catalysts behind Oscar Health’s share-price advance and improved profitability outlook. Oscar Health Rallies 14.9% in 3 Months: Can the Gains Keep Going?
• Positive Sentiment: Oscar Health was added to Zacks’ list of top-ranked growth stocks with a No. 1, or Strong Buy, ranking, which may attract momentum-oriented investors. Best Growth Stocks to Buy for October 13th
• Positive Sentiment: Zacks screens identified OSCR as both a strong-momentum stock and a potentially attractive value opportunity, helping support investor interest despite its recent gains. Why Fast-paced Mover Oscar Health Is a Great Choice for Value Investors
• Positive Sentiment: Some analysis suggests Oscar Health could be substantially undervalued after analysts raised earnings estimates and the company improved its 2026 outlook. These are valuation opinions rather than formal company guidance. Oscar Health Could Be 94% Undervalued Following Raised Earnings Estimates
• Neutral Sentiment: UBS maintained a Hold rating, indicating that the improved outlook may already be reflected in the stock and that investors should await more evidence of sustained execution. Oscar Health Receives a Hold from UBS
• Negative Sentiment: Analysts have highlighted Oscar Health’s relatively rich valuation, member-churn risk and rising medical costs, which could limit further upside if margins or membership trends disappoint. Is Oscar Health Stock a Buy as Growth Surges but Valuation Stays Rich?
• Negative Sentiment: UBS described the company’s third-quarter upside as less certain, with guidance reflecting positive trends but not eliminating concerns about the durability of growth and profitability. Oscar Health’s Q3 Upside Less Certain as Guidance Reflects Positive Trends, UBS Says

Analyst Ratings Changes

Several brokerages have issued reports on OSCR. The Goldman Sachs Group reissued a “neutral” rating and set a $34.00 target price on shares of Oscar Health in a research note on Thursday, September 17th. Zacks Research raised Oscar Health from a “hold” rating to a “strong-buy” rating in a research report on Monday, July 6th. Weiss Ratings raised Oscar Health from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Thursday, October 8th. Bank of America lifted their price target on Oscar Health from $28.00 to $30.00 and gave the company an “underperform” rating in a report on Thursday, September 17th. Finally, Raymond James Financial lifted their price target on Oscar Health from $34.00 to $42.00 and gave the company an “outperform” rating in a report on Friday, September 18th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $34.90.

Oscar Health Stock Performance

The firm’s fifty day moving average price is $31.26 and its 200 day moving average price is $26.41. The company has a current ratio of 1.09, a quick ratio of 1.09 and a debt-to-equity ratio of 0.21. The firm has a market capitalization of $10.56 billion, a PE ratio of 24.45, a PEG ratio of 0.37 and a beta of 2.47.

Oscar Health (NYSE:OSCR) last posted its quarterly earnings results on Thursday, August 6th. The company reported $1.10 earnings per share for the quarter, topping analysts’ consensus estimates of $0.40 by $0.70. Oscar Health had a net margin of 3.60% and a return on equity of 38.45%. The business had revenue of $4.88 billion for the quarter, compared to the consensus estimate of $4.73 billion. During the same period in the prior year, the business posted ($0.89) earnings per share. Oscar Health’s revenue for the quarter was up 70.4% compared to the same quarter last year. On average, research analysts anticipate that Oscar Health, Inc. will post 1.83 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Mario Schlosser sold 600,000 shares of Oscar Health stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $30.34, for a total transaction of $18,204,000.00. Following the completion of the sale, the director directly owned 480,866 shares in the company, valued at $14,589,474.44. The trade was a 55.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Richard Blackley sold 28,869 shares of Oscar Health stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $31.45, for a total value of $907,930.05. Following the sale, the chief financial officer owned 1,046,108 shares of the company’s stock, valued at approximately $32,900,096.60. This represents a 2.69% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last 90 days, insiders sold 874,451 shares of company stock worth $26,761,671. Insiders own 22.64% of the company’s stock.

Hedge Funds Weigh In On Oscar Health

A number of hedge funds have recently added to or reduced their stakes in OSCR. CoreCap Advisors LLC grew its position in Oscar Health by 526.3% in the second quarter. CoreCap Advisors LLC now owns 1,190 shares of the company’s stock worth $34,000 after acquiring an additional 1,000 shares in the last quarter. GAMMA Investing LLC increased its stake in shares of Oscar Health by 32.9% during the 2nd quarter. GAMMA Investing LLC now owns 1,441 shares of the company’s stock worth $41,000 after purchasing an additional 357 shares during the last quarter. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Oscar Health during the 1st quarter worth $49,000. FNY Investment Advisers LLC acquired a new position in shares of Oscar Health during the 2nd quarter worth $57,000. Finally, Allworth Financial LP raised its holdings in shares of Oscar Health by 124.9% during the 2nd quarter. Allworth Financial LP now owns 2,031 shares of the company’s stock valued at $58,000 after purchasing an additional 1,128 shares in the last quarter. Institutional investors and hedge funds own 75.70% of the company’s stock.

About Oscar Health

Oscar Health, Inc is a technology-driven health insurance company that provides health plans and related services to individuals, families and businesses in the United States. The company primarily serves members through plans offered under the Affordable Care Act (ACA), including individual and family coverage purchased through government marketplaces.

Oscar’s offerings include medical insurance plans with access to provider networks, prescription drug coverage and member support services.